Sabrina Serani is a senior editor for Targeted Oncology.
Acyclovir Prophylaxis Reduces Oral Mucositis Incidence in HSCT Recipients
February 18th 2024Adding prophylactic acyclovir therapy to the treatment regimen for patients undergoing a stem cell transplant reduced the rates of chemotherapy-induced oral mucositis, a common and significant adverse effect of the treatment.
Beyond Immunotherapy: New RCC Hope With TPST-1120 and Nivolumab Combo
February 4th 2024In an interview with Targeted Oncology, Bruno Bastos, MD, discussed how TPST-1120 can help address limited treatment options for patients with advanced renal cell carcinoma beyond immunotherapy and anti-VEGF tyrosine kinase inhibitors.